Addleshaw Goddard has advised artificial intelligence cardiovascular disease specialist GEN inCode UK Limited, on its GBP3 million institutional foundation fundraise from Maven Capital Partners and Downing LLP.
Addleshaw Goddard has advised artificial intelligence cardiovascular disease specialist GEN inCode UK Limited, on its GBP3 million institutional foundation fundraise from Maven Capital Partners and Downing LLP.
GEN inCode, which specialises in genetic risk assessment and prediction of cardiovascular disease through advanced genomic technology, will use the investment as a springboard for its rapid expansion and growth across the Europe, the UK and the US.
Addleshaw Goddard, which has a significant track-record in the life sciences sector, has supported GEN inCode since its incorporation and advised the Company on this GBP3 million institutional foundation investment. The deal was led by Corporate Finance partner, Anna Brown and Associate Michael Flett.
Partner, Anna Brown says “Advising GEN inCode on the next stage of its growth is a real privilege. The company’s diagnostic products and predictive capability has the capability to truly transform the assessment, treatment and prevention of cardiovascular disease. It can provide key information to patients, doctors and healthcare professionals enabling the application of both targeted therapies and the ability to effect lifestyle and behavioural changes.”
